TNFRSF18 and neoplasm: In conclusion, we demonstrated that incorporating an agonistic anti-GITR antibody into the initial TIL culture significantly enhances TIL proliferation, increases the proportion of CD8+ T cells and GzmB+ CD8+ effector cells, and improves anti-tumor efficacies both in vitro and in vivo.